RecruitingPhase 3NCT05327894
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Princess Maxima Center for Pediatric Oncology
- Principal Investigator
- Janine Stutterheim, DrPrincess Maxima Center for Pediatric Oncology in The Netherlands
- Intervention
- Blinatumomab(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 2022 – 2030
Study locations (30)
- Hospital de Pediatría S.A.M.I.C. "Juan P. Garrahan", Buenos Aires, Argentina
- Australian and New Zealand Children's Haematology/Oncology Group, Clayton, Victoria, Australia
- North Adelaide- Womens and Childrens Hospital, Adelaide, Australia
- Monash Children's Hosptial, Clayton, Australia
- New Lambton Heights- John Hunter Children's Hospital, New Lambton Heights, Australia
- Royal Children's Hospital (Children's Cancer Centre), Parkville, Australia
- Perth Children's Hospital, Perth, Australia
- Queensland Children's Hospital, South Brisbane, Australia
- Sydney Childrens Hospital, Sydney, Australia
- The Childrens Hospital at Westmead, Westmead, Australia
- Medical University Of Graz, Graz, Austria
- Medical University Of Innsbruck, Innsbruck, Austria
- Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH, Salzburg, Austria
- St. Anna Children's Hospital, Vienna, Austria
- Antwerp University Hospital, Antwerp, Belgium
- +15 more locations on ClinicalTrials.gov
Collaborators
University of Milano Bicocca · Amgen Europe B.V
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05327894 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University